inotuzumab ozogamicin治疗儿童复发/难治急性淋巴细胞白血病Ⅰ期研究
该Ⅰ期研究纳入25例≥1岁且<18岁的多次复发/难治CD22+急性淋巴细胞白血病患儿,评估inotuzumab ozogamicin的推荐Ⅱ期剂量。第1疗程后总缓解率为80%(95%CI 59%-93%),推荐Ⅱ期剂量确定为每疗程1.8 mg/m2,与成人一致。
要点
- 推荐Ⅱ期剂量为每疗程1.8 mg/m2(分次0.8、0.5、0.5 mg/m2)。
- 第1疗程后总缓解率80%,其中84%达MRD阴性完全缓解。
- 12个月总生存率40%,2例后续化疗后发生肝窦阻塞综合征。
核心结论
- inotuzumab ozogamicin在经多线治疗的儿童CD22+复发/难治ALL中耐受良好并显示抗白血病活性。
- 推荐Ⅱ期剂量确定为每疗程1.8 mg/m2,与成人相同。
研究设计与样本
- Ⅰ期剂量递增研究,纳入25例年龄≥1岁且<18岁的多次复发/难治CD22+ ALL患者,23例可评估剂量限制性毒性。
- 第1疗程第1、8、15天给药,剂量水平1为1.4 mg/m2(0.6、0.4、0.4 mg/m2),剂量水平2为1.8 mg/m2(0.8、0.5、0.5 mg/m2)。
主要发现
- 第1疗程后总缓解率为80%(95%CI 59%-93%),剂量水平1为75%(95%CI 43%-95%),剂量水平2为85%(95%CI 55%-98%)。
- 缓解者中84%(95%CI 60%-97%)达到MRD阴性完全缓解,12个月总生存率为40%(95%CI 25%-66%)。
- 23例发生3-4级不良事件,2例在后续化疗后报告肝窦阻塞综合征。
- 9例在inotuzumab ozogamicin后接受造血干细胞移植或嵌合抗原受体T细胞治疗。
- inotuzumab ozogamicin中位最大浓度与模拟成人浓度相当。
临床怎么用
- 儿童复发/难治CD22+ ALL可采用inotuzumab ozogamicin每疗程1.8 mg/m2分次给药,后续可桥接移植或CAR-T。
- 治疗期间需关注肝窦阻塞综合征风险,尤其后续化疗后。
局限性
- 样本量小(25例),为Ⅰ期剂量探索研究。
- 肝窦阻塞综合征发生于后续化疗后,与本品的直接关联需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patients (age ≥1 year or <18 years) received 3 doses of InO (days 1, 8, and 15) per course. Dose escalation was based on dose-limiting toxicities (DLTs) during course 1. Dose level 1 (DL1) was 1.4 mg/m2 (0.6, 0.4, 0.4 mg/m2) and DL2 was 1.8 mg/m2 (0.8, 0.5, 0.5 mg/m2). Secondary end points included safety, antileukemic activity, and pharmacokinetics. Twenty-five patients (23 evaluable for DLTs) were enrolled. In course 1, the first cohort had 1 of 6 (DL1) and 2 of 5 (DL2) patients who experienced DLTs; subsequent review considered DL2 DLTs to be non-dose-limiting. Dose was de-escalated to DL1 while awaiting protocol amendment to re-evaluate DL2 in a second cohort, in which 0 of 6 (DL1) and 1 of 6 (DL2) patients had a DLT. Twenty-three patients experienced grade 3 to 4 adverse events; hepatic sinusoidal obstruction syndrome was reported in 2 patients after subsequent chemotherapy. Overall response rate after course 1 was 80% (95% confidence interval [CI], 59% to 93%) (20 of 25 patients; DL1: 75% [95% CI, 43% to 95%], DL2: 85% [95% CI, 55% to 98%]). Of the responders, 84% (95% CI, 60% to 97%) achieved minimal residual disease (MRD)-negative complete response, and 12-month overall survival was 40% (95% CI, 25% to 66%). Nine patients received hematopoietic stem cell transplantation or chimeric antigen receptor T cells after InO. InO median maximum concentrations were comparable to simulated adult concentrations. InO was well tolerated, demonstrating antileukemic activity in heavily pretreated children with CD22+ R/R ALL. RP2D was established as 1.8 mg/m2 per course, as in adults. This trial was registered at https://www.clinicaltrialsregister.eu as EUDRA-CT 2016-000227-71.
引用
- Brivio E, Locatelli F, Lopez-Yurda M, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021. PMID: 33067614. doi:10.1182/blood.2020007848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。